{"id":"W3047911379","doi":"10.1111/cas.14605","title":"Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Science","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Novartis Pharma; Merck Sharp and Dohme; Ono Pharmaceutical; Astellas Pharma; Daiichi Sankyo Company; Clovis Oncology; Astellas Pharma Canada; Taiho Pharmaceutical; Boehringer Ingelheim; Bristol-Myers Squibb; AstraZeneca; Pfizer; Takeda Pharmaceutical Company; AbbVie; Kyowa Hakko Kirin","keywords":"Pembrolizumab; Medicine; Nivolumab; Internal medicine; Oncology; Lung cancer; Retrospective cohort study; Progressive disease; Disease; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001809626,0.0002428411,0.0003676405,0.0001149956,0.00007843822,0.00003014438,0.0003753848,0.00006181796,0.00008546118],"category_scores_gemma":[0.0000234901,0.0001950584,0.0001665196,0.001025244,0.0005693233,0.0001427736,0.00005567218,0.0001546136,9.590822e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003386774,"about_ca_system_score_gemma":0.001961336,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002217618,"about_ca_topic_score_gemma":0.00005275101,"domain_scores_codex":[0.9979476,0.00001747925,0.0003588429,0.0006804704,0.0003975021,0.0005981245],"domain_scores_gemma":[0.9988184,0.000045715,0.0001826579,0.0003166972,0.0002103053,0.000426218],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.04550452,0.001010691,0.2470827,0.001409935,0.00008651941,0.00008064376,0.006206232,0.0009810514,0.2530104,0.000005890635,0.0002577133,0.4443637],"study_design_scores_gemma":[0.02422472,0.001260578,0.304117,0.0009083042,0.0001536341,0.00000143909,0.0004427057,0.01551146,0.6467798,0.000007710294,0.005997241,0.0005954742],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9702227,0.02389365,0.001403579,0.00158169,0.0002562397,0.002479235,0.00006031606,0.0000347903,0.00006780749],"genre_scores_gemma":[0.9937252,0.001695649,0.001277682,0.00168312,0.0001521896,0.001333919,0.000005058228,0.00003054012,0.00009667291],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4437683,"threshold_uncertainty_score":0.795425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01732833794609896,"score_gpt":0.3128700621882125,"score_spread":0.2955417242421136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}